JPWO2022173033A1 - - Google Patents
Info
- Publication number
- JPWO2022173033A1 JPWO2022173033A1 JP2022580703A JP2022580703A JPWO2022173033A1 JP WO2022173033 A1 JPWO2022173033 A1 JP WO2022173033A1 JP 2022580703 A JP2022580703 A JP 2022580703A JP 2022580703 A JP2022580703 A JP 2022580703A JP WO2022173033 A1 JPWO2022173033 A1 JP WO2022173033A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021021684 | 2021-02-15 | ||
| JP2021021684 | 2021-02-15 | ||
| PCT/JP2022/005583 WO2022173033A1 (ja) | 2021-02-15 | 2022-02-14 | ４－アミノキナゾリン化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2022173033A1 true JPWO2022173033A1 (https=) | 2022-08-18 |
| JPWO2022173033A5 JPWO2022173033A5 (https=) | 2024-02-08 |
| JP7725511B2 JP7725511B2 (ja) | 2025-08-19 |
Family
ID=82838845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022580703A Active JP7725511B2 (ja) | 2021-02-15 | 2022-02-14 | ４－アミノキナゾリン化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240150366A1 (https=) |
| EP (1) | EP4293025B1 (https=) |
| JP (1) | JP7725511B2 (https=) |
| KR (1) | KR20230145360A (https=) |
| CN (1) | CN116867788A (https=) |
| AU (1) | AU2022219651A1 (https=) |
| CA (1) | CA3211110A1 (https=) |
| ES (1) | ES3054794T3 (https=) |
| MX (1) | MX2023009520A (https=) |
| PL (1) | PL4293025T3 (https=) |
| SA (1) | SA523450286B1 (https=) |
| WO (1) | WO2022173033A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2024008849A (es) | 2022-01-21 | 2024-07-25 | Usynova Pharmaceuticals Ltd | Compuestos de benzopirimidina y uso de estos. |
| AU2023231912A1 (en) * | 2022-03-11 | 2024-08-15 | Astellas Pharma Inc. | Heterocyclic compound for inducing degradation of g12d mutant kras protein |
| JP7733274B1 (ja) * | 2022-08-12 | 2025-09-02 | アステラス製薬株式会社 | Ｇ１２ｄ変異ｋｒａｓ阻害活性を有する二官能性化合物を含む抗がん剤の組合せ |
| AR130192A1 (es) * | 2022-08-12 | 2024-11-13 | Astellas Pharma Inc | Combinaciones antineoplásicas que comprenden quimioterapia |
| WO2024188281A1 (zh) * | 2023-03-13 | 2024-09-19 | 南京明德新药研发有限公司 | 含喹唑啉结构的化合物及其应用 |
| AU2024337913A1 (en) | 2023-09-08 | 2026-03-26 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| WO2025052649A1 (ja) * | 2023-09-08 | 2025-03-13 | アステラス製薬株式会社 | 単一の軸不斉化合物の選択的製造法 |
| US20250114339A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor |
| AU2024357850A1 (en) | 2023-10-09 | 2026-04-23 | Incyte Corporation | Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017172979A1 (en) * | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| WO2018143315A1 (ja) * | 2017-02-02 | 2018-08-09 | アステラス製薬株式会社 | キナゾリン化合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10011600B2 (en) | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
| WO2016049565A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Compositions and methods for inhibition of ras |
| US20220363681A1 (en) * | 2019-08-16 | 2022-11-17 | Genfleet Therapeutics (Shanghai) Inc. | Oxo six-membered cyclopyrimidine compound, preparation method and medical use thereof |
| WO2021041671A1 (en) | 2019-08-29 | 2021-03-04 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| WO2021106231A1 (en) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
-
2022
- 2022-02-14 AU AU2022219651A patent/AU2022219651A1/en active Pending
- 2022-02-14 US US18/546,330 patent/US20240150366A1/en active Pending
- 2022-02-14 WO PCT/JP2022/005583 patent/WO2022173033A1/ja not_active Ceased
- 2022-02-14 JP JP2022580703A patent/JP7725511B2/ja active Active
- 2022-02-14 KR KR1020237027664A patent/KR20230145360A/ko active Pending
- 2022-02-14 CN CN202280014859.0A patent/CN116867788A/zh active Pending
- 2022-02-14 ES ES22752855T patent/ES3054794T3/es active Active
- 2022-02-14 EP EP22752855.1A patent/EP4293025B1/en active Active
- 2022-02-14 PL PL22752855.1T patent/PL4293025T3/pl unknown
- 2022-02-14 MX MX2023009520A patent/MX2023009520A/es unknown
- 2022-02-14 CA CA3211110A patent/CA3211110A1/en active Pending
-
2023
- 2023-08-14 SA SA523450286A patent/SA523450286B1/ar unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017172979A1 (en) * | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| WO2018143315A1 (ja) * | 2017-02-02 | 2018-08-09 | アステラス製薬株式会社 | キナゾリン化合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4293025A4 (en) | 2025-02-26 |
| SA523450286B1 (ar) | 2024-06-12 |
| AU2022219651A1 (en) | 2023-09-07 |
| US20240150366A1 (en) | 2024-05-09 |
| MX2023009520A (es) | 2023-08-24 |
| EP4293025B1 (en) | 2025-10-29 |
| JP7725511B2 (ja) | 2025-08-19 |
| EP4293025C0 (en) | 2025-10-29 |
| PL4293025T3 (pl) | 2026-02-16 |
| WO2022173033A1 (ja) | 2022-08-18 |
| EP4293025A1 (en) | 2023-12-20 |
| CA3211110A1 (en) | 2022-08-18 |
| CN116867788A (zh) | 2023-10-10 |
| ES3054794T3 (en) | 2026-02-06 |
| KR20230145360A (ko) | 2023-10-17 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230612 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240131 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240809 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250522 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250527 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250729 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250806 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7725511 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |